3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Gynecologic
1
Gastrointestinal
1
CNS
1
Breast
1
Conditions
Triple Negative Breast Neoplasms
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Recurrence
1
Ovarian Neoplasms
1
Neoplasm Metastasis
1
Gastrointestinal Stromal Tumors
1
Fallopian Tube Neoplasms
1
Endometrial Neoplasms
1
Breast Neoplasms
1
Interventions
Docetaxel
8
pembrolizumab
7
Pemetrexed
5
Carboplatin
5
Erlotinib Hydrochloride
4
toripalimab
3
rociletinib
3
fludarabine
3
Radiosurgery
3
Paclitaxel
3
Oxaliplatin
3
Nivolumab
3
Gemcitabine
3
Etoposide
3
Cyclophosphamide
3
Cisplatin
3
Bevacizumab
3
lorlatinib
2
atezolizumab
2
Vinorelbine
2
Topotecan
2
Radiotherapy
2
Platinum
2
Itraconazole
2
Irinotecan
2
Interleukin-2
2
Cetuximab
2
Albumin-Bound Paclitaxel
2
vinflunine
1
vandetanib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recurrence
×
tinostamustine
×
Thoracic
×
Clear all
NCT03345485
2024-10-21
EDO-S101
Mundipharma Research Limited
Phase 1/2
Completed
71 enrolled
39 charts